Enobia Pharma develops therapies for the treatment of serious genetic bone disorders.
Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 18, 2005 | Series A | $15.55M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
T2C2 Capital | — | Series A |